?> Contact us Follow Us
Biosimilars Forum
  • About Us
    • Members
    • Executive Director
  • Why Biosimilars
    • The Issue
    • Our Solutions
  • Biosimilars 101
    • Foundations
    • Core Principles
    • FDA Regulatory Tenets
    • Biosimilars FAQs
    • Future Evolution of Biosimilar Development
    • Approved Biosimilars
  • Advocacy
    • Our Action
    • Tools
  • News
  • Resources
  • Get Involved
    • Partners

signalgroup

Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
News
January 24, 2024 signalgroup
Biosimilars Forum Welcomes Teva as Newest Member
News
January 10, 2024 signalgroup
Biosimilars Forum Welcomes Biocon Biologics as Newest Member
News
November 30, 2023 signalgroup
Julian Malasi Member Spotlight
News
November 16, 2023 signalgroup
Affordable prescription drugs exist — why can’t more patients access them?
News
November 3, 2023 signalgroup
Biosimilars Forum Supports Senate Finance Committee Legislative Discussion Draft Promoting Biosimilars
News
November 2, 2023 signalgroup
Biosimilars Forum Announces Support for Bipartisan Interchangeability Legislation
News
October 17, 2023 signalgroup
Biosimilars Forum Welcomes Meitheal Pharmaceuticals as Newest Member
News
October 10, 2023 signalgroup
Biosimilars Forum Welcomes Amneal as Newest Member
News
August 30, 2023 signalgroup
Biosimilars Forum Statement on CMS Announcement of Drug Negotiation List 
News
August 7, 2023 signalgroup
Biosimilars Forum Scientific Publication Identifies Pathway to Streamlined Development for Biosimilars
  • Prev page
  • 01
  • 02
  • 03
  • 04
  • Next page

  • Biosimilars 101
  • Biosimilars FAQs
  • Advocacy
  • Stay Connected
Biosimilars Forum
© 2025 Biosimilars Forum. All rights reserved.
  • Terms of Use
  • |
  • Privacy Policy
  • |
  • Contact Us